VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial

Karyopharm Therapeutics Executive Compensation (FY25)

KPTI · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Richard Paulson
Latest say-on-pay support
=
May 21, 2026
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Karyopharm Therapeutics brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (EX-10): July 17, 2026
13 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Karyopharm Therapeutics brief$500Get the executive brief
Velarion Intel, one year, every company
222 figures on this page: 214 cited to the filing that reported them, 8 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Richard Paulson: $2,069,341 → $2,320,902 (12.2% higher)
Say-on-pay support: 72.3% → 87.8% (15.5 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Karyopharm Therapeutics' chief executive and what were they paid?
Total compensation for Richard Paulson, President and Chief Executive Officer, came to $2,320,902 in fiscal 2025. Compared with the $2,069,341 reported for fiscal 2024, Paulson's total was 12.2% higher.
What was Karyopharm Therapeutics' say-on-pay result?
Shareholders supported the say-on-pay proposal with 87.8% of votes cast for or against in favor at the meeting held May 21, 2026 for fiscal 2025.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard Paulson
President and Chief Executive Officer
◇◇◇◇◇—◇◇
Michael Mason
Chief Financial Officer
◇—◇◇◇—◇◇
Sohanya Cheng
Chief Commercial Officer
◇—◇◇◇—◇◇
Stuart Poulton
Chief Development Officer
◇◇◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard Paulson
President and Chief Executive Officer
◇◇◇—◇—◇◇
Reshma Rangwala
Executive Vice President, Chief Medical Officer and Head of Research
◇—◇—◇—◇◇
Sohanya Cheng
Executive Vice President, Chief Commercial Officer and Head of Business Development
◇—◇—◇—◇◇
Michael Mason
Chief Financial Officer
◇—◇—◇—◇◇
Stuart Poulton
Chief Development Officer
◇—◇—◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard Paulson
President and Chief Executive Officer
◇—◇—◇—◇◇
Reshma Rangwala
Executive Vice President, Chief Medical Officer and Head of Research
◇—◇—◇—◇◇
Sohanya Cheng
Executive Vice President, Chief Commercial Officer and Head of Business Development
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard Paulson
President and Chief Executive Officer
◇◇◇◇◇—◇◇
Reshma Rangwala
Executive Vice President, Chief Medical Officer and Head of Research
◇◇◇◇◇—◇◇
Stuart Poulton
Executive Vice President, Chief Development Officer
◇◇◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Reshma RangwalaPSU——————◇
Richard PaulsonPSU——————◇
Sohanya ChengPSU——————◇
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Richard PaulsonRSU◇◇——
Option◇—◇2/27/2035
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/27/2032
Stuart PoultonRSU◇◇——
Option◇—◇2/27/2035
Option◇—◇2/27/2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇7/26/2032
RSU◇◇——
Option◇—◇2/27/2032
Reshma RangwalaOption◇—◇2/27/2035
Option◇—◇2/27/2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇4/28/2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Reshma Rangwala
Executive Vice President, Chief Medical Officer and Head of Research · Terms as announced by the company
Clawback◇
Richard Paulson
President and Chief Executive Officer · Terms as announced by the company
Clawback◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Barry E. Greene
Lead independent director
◇—◇———◇
Mansoor Raza Mirza, M.D
◇—◇——◇◇
Deepika R. Pakianathan, Ph.D
◇—◇———◇
Christy J. Oliger
◇—◇———◇
Garen G. Bohlin
◇—◇———◇
Chen Schor, M.B.A., C.P.A
◇—◇———◇
Zhen Su, M.D., M.B.A
◇—◇———◇
Richard Paulson, M.B.A served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Alpine symbol not shown

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 21, 2026=◇◇◇
2024May 28, 2025=◇◇◇
2023May 29, 2024=◇◇◇
2022May 24, 2023=◇◇◇
2021May 19, 2022=◇◇◇
2020May 21, 2021=◇◇◇
2019May 21, 2020=◇◇◇
2018June 6, 2019=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Richard Paulson (President and Chief Executive Officer), FY2025 total compensation $2,320,902 (base salary $770,000) [exec_comp, SEC accession 0001503802-26-000023, filed 2026-04-13]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Karyopharm Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Karyopharm Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Karyopharm Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Karyopharm Therapeutics' disclosed peer group is defensible, who names Karyopharm Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
222 figures on this page: 214 cited to the filing that reported them, 8 calculated from figures it prints.
214 cited to the filing
8 calculated from the filing

Documents cited

  1. 0001193125-26-307964
    Exhibit
  2. 0001503802-26-000027
    063 5,410,881 4. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.
  3. 0001503802-26-000023
    025 Summary Compensation Table · Director Compensation · Outstanding Equity Awards at December 31, 2025
  4. 0000950170-25-079009
    880 2,509,033 3. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.
  5. 0000950170-25-053511
    024 Summary Compensation Table · EXECUTIVE COMPENSATION
  6. 0001193125-24-151049
  7. 0000950170-24-045717
    2023 Summary Compensation Table
  8. 0001193125-23-154191
  9. 0000950170-23-012367
    2023 Summary Compensation Table
  10. 0001193125-22-157447
  11. 0001193125-21-170821
  12. 0001193125-20-151512
  13. 0001193125-19-168167
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Karyopharm Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/KPTI (accessed 2026).
Short form: data: Velarion

The Karyopharm Therapeutics brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
13 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Karyopharm Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy